A new report tied to the Milken Institute highlighted reimbursement friction as a core headwind for women’s health startups, urging early planning for coverage strategy when clinical evidence and payer confidence are limited. The analysis frames the issue as structural: many products entering the category face difficulty translating early-stage data into payer-ready dossiers, increasing the risk of delayed coverage decisions. It also recommends building reimbursement considerations into development plans rather than treating them as a late-stage exercise. For biotech companies focused on women’s health, the update signals that commercial readiness—including evidence generation aligned to payer expectations—may be as critical as clinical endpoints. Industry participants are likely to watch how developers adjust evidence packages and payer engagement as reimbursement pathways tighten.